Life-threatening toxicity in a patient with UGT1A1*6 heterozygous polymorphism after irinotecan-based chemotherapy: a case report

Daiki Ogawara; Minoru Fukuda; Yoichi Nakamura; Katsumi Nakatomi; Kohei Motoshima; Hiroaki Senju; Kousuke Mizoguchi; Shinnosuke Takemoto; Takuya Honda; Kazuto Ashizawa; Yoshinori Hasegawa; Shigeru Kohno

doi:10.11343/amn.59.63

CASE REPORT

Life-threatening toxicity in a patient with UGT1A1*6 heterozygous polymorphism after irinotecan-based chemotherapy: a case report

Daiki Ogawara, Minoru Fukuda, Yoichi Nakamura, Katsumi Nakatomi, Kohei Motoshima, Hiroaki Senju, Kousuke Mizoguchi, Shinnosuke Takemoto, Takuya Honda, Kazuto Ashizawa, Yoshinori Hasegawa, Shigeru Kohno

Author information

Daiki Ogawara
Second Department of Medicine, Nagasaki University Hospital
Minoru Fukuda
Second Department of Medicine, Nagasaki University Hospital
Clinical Oncology Center, Nagasaki University Hospital
Yoichi Nakamura
Second Department of Medicine, Nagasaki University Hospital
Katsumi Nakatomi
Second Department of Medicine, Nagasaki University Hospital
Kohei Motoshima
Second Department of Medicine, Nagasaki University Hospital
Hiroaki Senju
Second Department of Medicine, Nagasaki University Hospital
Kousuke Mizoguchi
Second Department of Medicine, Nagasaki University Hospital
Shinnosuke Takemoto
Second Department of Medicine, Nagasaki University Hospital
Takuya Honda
Clinical Oncology Center, Nagasaki University Hospital
Kazuto Ashizawa
Clinical Oncology Center, Nagasaki University Hospital
Yoshinori Hasegawa
Department of Respiratory Medicine, Nagoya University Hospital
Shigeru Kohno
Second Department of Medicine, Nagasaki University Hospital

Keywords: UGT1A1*6 polymorphism, irinotecan, lung cancer

JOURNAL FREE ACCESS

2014 Volume 59 Issue 2 Pages 63-65

DOI https://doi.org/10.11343/amn.59.63

Details

Abstract

Polymorphism of the UGT1A1 gene is known to play an important role in irinotecan pharmacokinetics and severe toxicity. A 71-year-old man with lung cancer (squamous cell carcinoma cT2aN3M0 stage IIIB) received irinotecan and cisplatin with concurrent thoracic radiotherapy. Although all treatments were discontinued after day 7, severe leukopenia, neutropenia, febrile neutropenia, thrombocytopenia, and diarrhea developed. His life was at risk, and his ECOG performance status (PS) fell to 4. He had UGT1A1*6 heterozygous and UGT1A1*28 wild-type gene polymorphisms. Considering its frequency in Asians, we should take care when using irinotecan to treat patients with UGT1A1*6 heterozygous polymorphism.

Corresponding author

Register with J-STAGE for free!